VWF and thrombotic thrombocytopenic purpura: The current treatment of TTP in the acute phase is based on urgent PEx, combined with corticosteroid therapy, B-cell-targeted immunotherapy, rituximab and the inhibition of the interaction between ultralarge VWF multimers and platelets, using caplacizumab, a monoclonal antibody [12].